Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
Background Immunotherapy has determined unprecedented long-term responses in several
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …
Clinical challenges of immune checkpoint inhibitors
M de Miguel, E Calvo - Cancer cell, 2020 - cell.com
Even though the immuno-oncology (IO) era has achieved many successes, some signs of
research development deceleration are arising. Recently, the number of FDA …
research development deceleration are arising. Recently, the number of FDA …
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
The gut microbiome has been shown to influence the response of tumors to anti–PD-1
(programmed cell death–1) immunotherapy in preclinical mouse models and observational …
(programmed cell death–1) immunotherapy in preclinical mouse models and observational …
Systemic treatment of hepatocellular carcinoma: An EASL position paper
The last 5 years have witnessed relevant advances in the systemic treatment of
hepatocellular carcinoma. New data have emerged since the development of the EASL …
hepatocellular carcinoma. New data have emerged since the development of the EASL …
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
LB Kilburn, DA Khuong-Quang, JR Hansford, D Landi… - Nature medicine, 2024 - nature.com
BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade
glioma (pLGG). Arm 1 (n= 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial …
glioma (pLGG). Arm 1 (n= 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial …
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell …
Objective Programmed death 1 and its ligand 1 (PD-1/PD-L1) immunotherapy is promising
for late-stage lung cancer treatment, however, the response rate needs to be improved. Gut …
for late-stage lung cancer treatment, however, the response rate needs to be improved. Gut …
The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study
The primary endpoint of MOUSEION-01 was to assess overall survival (OS) in male and
female patients receiving immune checkpoint inhibitors versus control treatments …
female patients receiving immune checkpoint inhibitors versus control treatments …
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
T Andre, E Elez, E Van Cutsem… - … England Journal of …, 2024 - Mass Medical Soc
Background Patients with microsatellite-instability–high (MSI-H) or mismatch-repair–
deficient (dMMR) metastatic colorectal cancer have poor outcomes with standard …
deficient (dMMR) metastatic colorectal cancer have poor outcomes with standard …
Hepatocellular carcinoma immunotherapy
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the third
leading cause of cancer-related death worldwide. Single-agent anti-PD-1 immune …
leading cause of cancer-related death worldwide. Single-agent anti-PD-1 immune …
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Q Li, J Han, Y Yang, Y Chen - Frontiers in Immunology, 2022 - frontiersin.org
Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide.
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …